FDA panel says OK to Vivitrol for opioid dependence

An FDA panel has recommended that Vivitrol, a drug that treats alcohol dependence through a drug-delivery technology by Alkermes, also be allowed to treat addiction to opioids like heroin. The FDA's Psychopharmacologic Drugs Advisory Committee voted 12 to 1 in favor. The FDA is set to make a decision by Oct. 12.

What makes Vivitrol effective is Alkermes’ proprietary, injectable extended-release technology called Medisorb, which enables sustained releases over long periods of time. Vivitrol, for example, is injected only once a month. The company says the technology allows us it to encapsulate small molecules, peptides and proteins in microspheres made of biodegradable polymers with extended-release profiles lasting from days to months.

The Associated Press reports that some doctors already prescribe Vivitrol off-label as a treatment for opioid addiction, so if the FDA grants the new approval, sales are not going to jump right away.

- read the Alkermes release
- learn about Medisorb
- read the AP report
- and see how the company’s stock responded

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.